The trispecific antibody market is rapidly advancing, with 50+ candidates in clinical trials and first approvals expected by 2028. These next-gen immunotherapies target three distinct antigens, ...

The design of multispecific antibodies is also possible, as illustrated by ABS-VIR-001, a trispecific antibody designed as a prophylaxis and therapeutic against SARS-CoV-2 infection. Using in ...

The humanised trispecific antibody is undergoing Phase I clinical trials in the US and China in subjects with relapsed or refractory multiple myeloma (MM). Simcere Zaiming will gain an upfront ...

Mabylon AG recently provided preclinical data for MY-006, a half-life extended trispecific anti-peanut antibody being developed for the treatment of peanut allergy. BioWorld Science Conferences Immune ...

The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

Cancer treatment is one of the biggest challenges of modern medicine. Research has shown that immune cells can be trained and modified to fight cancer cells. Disclaimer: AAAS and EurekAlert! are ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

CS2009, an innovative trispecific antibody designed and developed by CStone, combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional anti-tumor effects ...

A next generation of trispecific PD-(L)xVEGF antibodies with a third specificity may even further improve the clinical benefit. Nearly all of the PD-(L)1xVEGF antibody development candidates in ...